Archer Materials Stock AXE.AX
Archer Materials is an early-stage Australian technology company developing two proprietary platforms: the 12CQ quantum computing chip, built on carbon-based graphene qubit spin technology licenced from the University of Sydney, and a point-of-care Biochip medical diagnostics platform targeting rapid clinical testing. Archer Materials stock (AXE.AX): Annual results since 2023 from Annual Report and IR documents: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, annual reporting. Stock analysis by NadirAlpha. Archer Materials stock (AXE.AX): listed on ASX. NadirAlpha has evaluated 7 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Latest reported (FY2026 (Jul 2025 to Jun 2026)): Net tangible assets per share, Interest income, Short-term deposits. Latest reading: Partnership, Net income turned positive.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Archer Materials Current Status
The current state of Archer Materials at a glance, figures as of FY2026, with core figures and the key management statements from the latest filing. NadirAlpha methodology
Assessment by NadirAlpha, as of FY2026 (Jul 2025 to Jun 2026).
“We do not intend to wait for a future quantum computer to arrive in Australia before building the business around it.”
“Each project has moved to its next stage, with a greater emphasis on the engineering, manufacturing and commercial work that will be required if Archer is to successfully achieve product commercialisation.”
Archer Materials Stock: Key Figures (A$ million)
NadirAlpha shows fiscal years, half-years and quarters of Archer Materials one below the other, most recently FY2026; every figure is clickable and leads to raw value, location and source. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Calendar quarter | Net income | EPS (A$) | OCF | Source |
|---|---|---|---|---|---|
| FY2026 | Q3/2025–Q2/2026 | -6.4 | -2.50 | -5.3 | 5 |
| FY2025 | Q3/2024–Q2/2025 | -7 | -2.74 | -4.2 | 1 |
| FY2024 | Q3/2023–Q2/2024 | -4.8 | -1.88 | -4.8 | 101 |
Archer Materials Balance Sheet & Cash Flow (A$ million)
Point-in-time balance sheet items of Archer Materials (cash, financial debt) and cash flow items per fiscal year, half-year and quarter, derived values with their formula in the popover. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Calendar quarter | Published | Cash | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | Q3/2025–Q2/2026 | 2026-07-09 | 1.8 | -5.3 | 0 | -5.3 | 5 |
| FY2025 | Q3/2024–Q2/2025 | 2025-08-31 | 2.7 | -4.2 | – | – | 1 |
| FY2024 | Q3/2023–Q2/2024 | 2025-08-31 | 2.8 | -4.8 | – | – | 101 |
Quarters
| Period | Calendar quarter | Published | Cash | Source |
|---|---|---|---|---|
| 2025-Q4 | Q2/2025 | 2025-08-31 | 2.7 | 101 |
| 2024-Q4 | Q2/2024 | 2025-08-31 | 2.8 | 101 |
Archer Materials Stock: Price & Chart
Price history of Archer Materials stock (AXE.AX) as a TradingView chart, loaded only after a click, alongside the trend of the key figures from the tables. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Archer Materials Event Timeline
What happened at Archer Materials since 2023: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology
2026 · 6 events
Net loss decreased to 6.4 million from $6.97 million in FY2025, an improvement of 8.8% driven by lower share-based payments expense 6
Expanded Biochip platform via collaboration with IMEC to include silicon-based sensors offering faster readout and lower manufacturing risk 6
“We've had a tremendous quarter for the business, alongside significant commercial momentum, we also delivered across all three pillars of our technology portfolio. To have all programs making consistent progress in the most exacting and challenging markets in the world is a testament to the enormous talent of the Archer team.”
Announced strategic Quantum Compute Agreement with IonQ Inc. to leverage global quantum compute power for algorithm development 5
Demonstrated QNN fraud detection on commercial quantum hardware, detecting 18 of 19 fraudulent transactions in simulation and quantum hardware environments 5
“We also progressed our partnership with Emergence Quantum, laying the groundwork for identifying graphene-based prototype applications.”
Created Biochip alpha-prototype demonstrating clinically relevant potassium accuracy within ±0.3 mM; beta-prototype planned for later in 2026 4
Progressing collaboration with Emergence Quantum on graphene-based prototype applications; second phase to demonstrate prototypes in high-impact applications 4
2025 · 5 events
“Archer is not just designing chips; the team is building the technological backbone of tomorrow by eliminating key technical risks and solidifying the company's patent portfolio.”
FY2025 net loss widened to 7M from AUD 4.80M in prior year; ChemX Materials investment written to zero (one-off impairment following voluntary administration) contributed to the increase 1
Qubit chip: strong coupling between carbon-based spin material and superconducting resonator demonstrated; coherence lifetimes reached approximately 800 ns, up from 385 ns; Coulomb blockade achieved at room temperature 1
Biochip gFET chip size reduced 97% to 1.5mm x 1.5mm; Paragraf Limited and Hylid Diagnostics Inc. partnerships formed for blood potassium testing; TMR sensor program launched targeting AI, automotive, and IoT markets 1
Dr Simon Ruffell appointed CEO on 27 March 2025, previously serving as Chief Technology Officer 1
Archer Materials Business Model
The Archer Materials business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology
Archer Materials is an early-stage Australian technology company developing two proprietary platforms: the 12CQ quantum computing chip, built on carbon-based graphene qubit spin technology licenced from the University of Sydney, and a point-of-care Biochip medical diagnostics platform targeting rapid clinical testing. Neither platform has reached commercialisation and the company records no operating revenue. Archer funds its operations through equity capital raisings and Australian government R&D tax incentive programmes. In FY2026 the 12CQ program demonstrated two readout methods (EDMR and single-electron transistors) and achieved carbon qubit synthesis on a one-inch silicon wafer with electron spin lifetimes exceeding 0.4 microseconds at room temperature. The Biochip platform reached integrated alpha prototype stage, with the IMEC collaboration extended to silicon-based sensors and beta prototype development underway for external laboratory and pre-clinical evaluation. A post-period Quantum Compute Agreement with IonQ provides cloud-based quantum computing access for a three-year term, and a CSIRO joint project commenced in November 2025 targets quantum machine-learning software for financial fraud detection. The intended path to monetisation runs through advancing both platforms to foundry-ready and pre-clinical evaluation stages before engaging commercialisation partners for licensing or co-development arrangements.
Archer Materials Stock: Share-Price Drivers
What determines the business trajectory of Archer Materials according to management, summarised from the reports up to FY2026. NadirAlpha methodology
With no product revenue reported, the company's cash position is the key resource for continued development, standing at 2.7 million at the latest quarter against 2.8 million a year earlier and 0.8 million the year before, 101
Archer entered a Strategic Quantum Compute Agreement with IonQ in July 2026, adding an external collaboration alongside its in-house 12CQ programme, 5
The Biochip is gaining traction as it moves through the pipeline, with an integrated alpha prototype completed around mid-2026 and beta-prototype development and external laboratory evaluation planned next, 6
Archer continues to target a foundry-ready demonstration and a qubit demonstrator for the 12CQ chip, which remain planned rather than completed milestones, 5
Archer Materials completed a $7 million share placement and launched a Share Purchase Plan for eligible shareholders in Australia and New Zealand during the latest quarter, 5
Archer maintains a CSIRO joint project on quantum machine-learning for fraud detection and expanded its IMEC collaboration toward silicon-based sensors, 6
Sector trend: Archer operates in pre-commercial deep technology across quantum computing, medical diagnostics and sensing, where no revenue, margin or utilisation KPIs are yet reported; progress is measured by prototype milestones and funding rather than sector demand metrics, 101
Archer Materials Products & announcements (16/16 active+recent)
What Archer Materials launched, had approved or announced, from the filings up to FY2026, each row with the date of first mention. NadirAlpha methodology
Status: PlannedLaunchedStable
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2026 | |||
| Share Purchase Plan for eligible shareholders in Australia and New Zealand | 2026-12 | 5 | |
| Biochip beta prototype external laboratory evaluation and pre-clinical studies | 2026-12 | 5 | |
| 12CQ quantum chip foundry-ready demonstration | 2026-12 | 5 | |
| $7 million share placement | 2026-12 | 5 | |
| Share Purchase Plan issuance | 2026-08 | 7 | |
| Placement tranche 1 | 2026-07 | 7 | |
| Qubit demonstration | 2026-06 | 1 | |
| Biochip alpha prototype completion (2x) | 2026-06 | 6 | |
| Quantum qubit demonstrator device | 2026 | 4 | |
| IMEC collaboration expansion to silicon-based sensors | 2026 | 6 | |
| Full Quantum Machine Learning prototype for fraud detection | 2026 | 4 | |
| Biochip clinical trials prototype (2x) | 2026 | 1 | |
| Biochip beta prototype development (3x) | 2026 | 7 | |
| 2025 | |||
| Blood potassium sensing lab demonstration | 2025-12 | 1 | |
| CSIRO joint project for quantum machine-learning software (2x) | 2025-11 | 7 | |
| TMR sensor commercialisation pathway establishment | 2025 | 1 | |
Archer Materials Transactions & Events (2)
Transactions of Archer Materials since 2023: acquisitions, disposals, agreements and regulation, deliberately including smaller items; purchase prices only when the company names them. NadirAlpha methodology
Divestitures and exits by Archer Materials
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2024 | |||
| ChemX Materials Limited ASX suspension | 2024-12 | Divested | 1 |
Partnerships and contracts of Archer Materials
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| IonQ Quantum Compute Agreement (2x) | 2026-07 | Agreement | 5 |
Archer Materials Risks (35 since the annual report of 2026-08-27, 38 tracked in total)
NadirAlpha lists 35 active risks of Archer Materials from the filings, the category as a coloured dot with legend, the wording as a short summary of the filing with no assessment of our own. NadirAlpha methodology
Category: FinancialLegalTechnologyMacroCustomersRegulatoryPeopleMarket
| Risk | Category | Last reported |
|---|---|---|
| Archer Materials: first mention in IR-Annual annual report of 2026-08-27 (FY2026), source 7 | ||
| ChemX Materials Limited suspended from ASX in December 2024 and appointed voluntary administrators in January 2025, impacting Archer's entitlement to 2% Net Smelter Return royalty | = | |
| Company is pre-revenue and dependent on capital raisings and R&D tax incentives | = | |
| Group assessed ability to continue as going concern with adequate resources to operate for at least 12 months | = | |
| University of Sydney licence agreement termination would prevent commercialisation of 12CQ quantum technology | = | |
| IonQ agreement termination would prevent access to purchase IonQ quantum computer | = | |
| Dispute with Witchimag counterparts over $150,000 CAD bonus payment entitlement from Mineral Road Discovery Inc listing transaction | = | |
| No guarantee experiments will succeed or that technologies will be commercially viable | = | |
| Risk that intellectual property may lack adequate patent protection or scope insufficient in certain jurisdictions | = | |
| Group exposed to foreign exchange risk primarily with respect to United States Dollar | = | |
| Market acceptance of quantum computing and medical diagnostics not guaranteed despite successful development | = | |
| Archer Materials: first mention in IR-Annual annual report of 2026-08-26 (FY2026), source 6 | ||
| Operating cash outflow of $5,253,164 in FY2026, cash reserves declining from $2,661,950 to $1,845,647 | = | |
| No guarantee Archer will find suitable customers and partners to justify purchase of IonQ quantum computer for Australian sovereign capability. | = | |
| Transaction with IonQ depends on agreement remaining in force; termination would prevent access to IonQ quantum computer. | = | |
| Patents and licences under prosecution; licences require annual fees to continue access | = | |
| Development of 12CQ technology depends on Licence Agreement with University of Sydney remaining in place; termination would prevent commercialisation. | = | |
| Medical technologies must meet TGA, FDA and European regulatory standards; non-compliance or delays could stall product development. | = | |
| Commercially exploiting IP including graphene biochip technology dependent on patent protection; third-party claims could affect owned or licensed IP. | = | |
| No material financial debt; Group relies on cash reserves and equity financing | = | |
| Contingent assets relating to land option, royalty, and bonus payment entitlements with uncertain realization | = | |
| Exposure to listed investment price risk from equity securities held | = | |
| Quantum sector regulation evolving with increasing global attention on data security and dual-use technology; failure to meet emerging obligations could limit market access. | = | |
| Access to institutional scale infrastructure shutdowns would restrict development activities during closures | FY2026 2026-08-27 7 | |
| Archer Materials: first mention in IR-Annual annual report of 2025-08-31 (FY2025), source 1 | ||
| Company relies on capital raisings and R&D tax incentives to fund operations; ability to develop technology contingent on timely funding access. | FY2026 2026-08-26 6 | |
| Unable to find suitable commercialisation partners could limit growth strategy and customer base development | FY2026 2026-08-27 7 | |
| Loss of key personnel with unique quantum and biochip technology knowledge could materially delay projects | FY2026 2026-08-27 7 | |
| Medical technologies must meet strict TGA/FDA/European agency safety and performance standards before commercialisation | FY2026 2026-08-27 7 | |
| Group exposed to interest rate risk with sensitivity impact of $36,913 per 2% rate change on loss and equity | FY2026 2026-08-27 7 | |
| General economic conditions and currency exchange rates may adversely affect funding ability | FY2026 2026-08-27 7 | |
| Quantum computing is emerging; new medical diagnostic tools may face resistance from clinicians and healthcare systems despite technical viability. | FY2026 2026-08-26 6 | |
| Emerging regulatory obligations around data security and cryptography in quantum sector may create compliance challenges | FY2026 2026-08-27 7 | |
| Potential bonus payment entitlement from Leigh Creek Project sale up to C$150,000 if Witchimag lists on stock exchange; counterparties deny obligation. | = | |
| Archer entitled to 2% Net Smelter Return royalty from ChemX Materials on minerals extracted from sold tenements; CMX administration may impact future entitlement. | = | |
| Third-party IP claims risk; patent protection scope may be insufficient or patents deemed invalid in certain jurisdictions. | = | |
| Quantum technology development depends on Licence Agreement with University of Sydney; termination would prevent IP commercialisation. | = | |
| Option to buy back approximately 30% of Sugarloaf farmland exercisable anytime before 4 December 2028; not assigned to iTech Minerals Ltd. | = | |
Archer Materials Reported KPIs (as disclosed) (35)
The story KPIs of Archer Materials that standard databases usually miss, grouped by publication, most recent first, with source number. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| Archer Materials, published 2026-08-27, period FY2026 | ||
| Weighted average number of ordinary shares diluted | 254,847,013 | 7 |
| Weighted average number of ordinary shares basic | 254,847,013 | 7 |
| Short-term deposits | 6,573,366 | 7 |
| Net tangible assets per share | 3.96 cents | 7 |
| Interest income | 479,104 | 7 |
| Archer Materials, published 2026-08-26, period FY2026 | ||
| Unlisted options on issue | 17,250,000 | 6 |
| Shares on issue | 254,847,013 | 6 |
| Performance rights on issue | 2,114,960 | 6 |
| Net tangible assets per share | 3.96 cents | 6 |
| Interest income | 479,104 | 6 |
| Archer Materials, published 2026-07-09, period 2026-Q4 | ||
| Estimated quarters of funding available | 4.51 | 5 |
| Call deposits | 6,560 (AUD $A'000) | 5 |
| Bank balances | 1,846 | 5 |
| Archer Materials, published 2026-04-29, period 2026-Q3 | ||
| Staff costs YTD | (2,654) | 4 |
| Staff costs | (852) | 4 |
| Research and development payments YTD | (2,080) | 4 |
| Research and development payments | (680) | 4 |
| Interest received YTD | 596 | 4 |
| Interest received | 39 | 4 |
| Government grants and tax incentives YTD | 2,102 | 4 |
| Government grants and tax incentives | 2,102 | 4 |
| Cash position | $10.3 million | 4 |
| Administration and corporate costs YTD | (1,212) | 4 |
| Administration and corporate costs | (473) | 4 |
| Archer Materials, published 2025-08-31, period FY2025 | ||
| Term deposits short term | 11,082,750 | 1 |
| Loss after income tax | (6,972,006) | 1 |
| Listed investment in Volatus Capital Corp shares | 73,100 | 1 |
| Interest income | 743,288 | 1 |
| Unlisted share options | 17,250,000 | 1 |
| Total comprehensive loss for the year | (6,972,006) | 1 |
| Share-based payments expense | 1,889,842 | 1 |
| Quantum and biochip technology research expenditure | 4,791,577 | 1 |
| Ordinary shares on issue | 254,847,013 | 1 |
| Fair value loss on financial assets | 455,227 | 1 |
| Depreciation expense | 133,445 | 1 |
Archer Materials Development
A condensed summary of Archer Materials per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. NadirAlpha methodology
FY2026: Archer Materials
Archer Materials posted a net loss of 6.4 million for FY2026, down 8.8% from $6.97 million in FY2025, with the improvement driven by lower share-based payments expense 6. Operating cash outflow was 5.3 million, and cash at 30 June 2026 stood at 1.8 million with no corporate debt 6. The 12CQ quantum computing program demonstrated two qubit readout methods and achieved synthesis of carbon qubit material on a one-inch silicon wafer with electron spin lifetimes exceeding 0.4 microseconds at room temperature 6. The Biochip medical diagnostics platform advanced from alpha to beta prototype phase, with a collaboration with IMEC expanding the platform to silicon-based sensors offering faster readout and lower manufacturing risk 6. Post-period, Archer Materials signed a three-year Quantum Compute Agreement with IonQ Inc. and completed a capital placement raising approximately $6.86 million before costs, followed by a Share Purchase Plan raising $953,321 before costs 6.
FY2025: Archer Materials
Archer Materials Limited reported a net loss of 7 million for FY2025 (year ended 30 June 2025), compared with AUD 4.80 million in the prior year, with operating cash outflow of 4.2 million and closing cash of 2.7 million 1. The period included a leadership transition: Dr Mohammad Choucair departed as CEO on 14 October 2024 and Dr Simon Ruffell, previously Chief Technology Officer, was appointed on 27 March 2025 1. On the qubit chip program, the company demonstrated strong coupling between its carbon-based spin material and a superconducting resonator, extending coherence lifetimes to approximately 800 nanoseconds from 385 nanoseconds, and demonstrated Coulomb blockade at room temperature 1. The Biochip program achieved a 97% reduction in gFET chip size to 1.5mm x 1.5mm, enabling yields of up to 1,375 chips per four-inch wafer, supported by new partnerships with Paragraf Limited and Hylid Diagnostics Inc. targeting at-home blood potassium testing 1. A new TMR sensor program was launched targeting AI, automotive, and IoT markets, while the company's investment in ChemX Materials Limited (ASX: CMX) was written down to zero following ChemX's entry into voluntary administration in January 2025 1.
Glossary
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
The evidence base for Archer Materials stock: every document with type and date, every figure in the report leads here by number and to the original by link. NadirAlpha methodology
| # | Document type | Published |
|---|---|---|
| #1 / #101 | IR-Annual annual report | 2025-08-31 |
| #4 | IR-Quarter quarterly report | 2026-04-29 |
| #2 | IR-Quarter quarterly report | 2026-05-04 |
| #3 | IR-Report report | 2026-06-04 |
| #5 | IR-Quarter quarterly report | 2026-07-09 |
| #6 | IR-Annual annual report | 2026-08-26 |
| #7 / #107 | IR-Annual annual report | 2026-08-27 |
Archer Materials Stock FAQ
Which additional key figures does Archer Materials report?
As reported for FY2026 (Jul 2025 to Jun 2026): Net tangible assets per share, Interest income, Short-term deposits, Unlisted options on issue, Performance rights on issue. The chapter Reported KPIs lists every value with its source.
Where can I find the official investor relations documents of Archer Materials?
NadirAlpha links all 7 original filings used (IR documents) in the sources chapter: annual report, quarterly report, report, each with type, publication date and a direct link; every figure in the report carries a source number.
More reports by NadirAlpha
Recently updated
Comparable stocks: Semiconductors & Semiconductor Equipment from Australian
All reports · Australian Stocks (3) · Technology Stocks (13)